Publication date: Sep 19, 2023
Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. A considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule. In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG
| Concepts | Keywords |
|---|---|
| Kidney | COVID-19 |
| Mrna | kidney transplantation |
| Naive | randomized trial |
| Vaccination | SARS-CoV-2 mRNA vaccine |
| SARS-CoV-2 vaccination |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | VO | vaccination |
| disease | VO | vaccine |
Original Article
(Visited 1 times, 1 visits today)